Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

HS Rugo; S Loi; S Adams; P Schmid; A Schneeweiss; CH Barrios; H Iwata; VC Dieras; EP Winer; M Kockx; D Peeters; SY Chui; JC Lin; A Nguyen Duc; G Viale; L Molinero; LA Emens

Conference Proceedings

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

HS Rugo, S Loi, S Adams, P Schmid, A Schneeweiss, CH Barrios, H Iwata, VC Dieras, EP Winer, M Kockx, D Peeters, SY Chui, JC Lin, A Nguyen Duc, G Viale, L Molinero, LA Emens

ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019

DOI: 10.1093/annonc/mdz394.009

Abstract

Background IMpassion130 is a Ph 3 study evaluating atezolizumab (A) + nab-paclitaxel (nP) vs placebo (P) + nP as 1L treatment for patients (pts) with mTNBC. A+nP significantly improved PFS in PD-L1+ pts (PD-L1 positivity defined as PD-L1–stained immune cells [IC] ≥ 1% of the tumour area by VENTANA PD-L1 SP142 assay). PD-L1+ pts also had clinically meaningful OS benefit with A+nP (25 vs 18mo; HR 0.71 [95% CI: 0.54, 0.93]; median follow-up, 18mo; Schmid, ASCO 2019). In this exploratory post-hoc analysis, we evaluated the analytical concordance of SP142 with 2 other PD-L1 IHC assays, and their ability to predict clinical activity. Methods Available samples from IMpassion130 were evaluated for P..

View full abstract